JP2014514323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514323A5 JP2014514323A5 JP2014506609A JP2014506609A JP2014514323A5 JP 2014514323 A5 JP2014514323 A5 JP 2014514323A5 JP 2014506609 A JP2014506609 A JP 2014506609A JP 2014506609 A JP2014506609 A JP 2014506609A JP 2014514323 A5 JP2014514323 A5 JP 2014514323A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycle
- heteroaryl
- aryl
- carbocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 244
- 125000000623 heterocyclic group Chemical group 0.000 claims description 178
- 125000001072 heteroaryl group Chemical group 0.000 claims description 164
- 125000003118 aryl group Chemical group 0.000 claims description 153
- 125000001188 haloalkyl group Chemical group 0.000 claims description 99
- 125000000304 alkynyl group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 69
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 61
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000002837 carbocyclic group Chemical group 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 208000037357 HIV infectious disease Diseases 0.000 claims description 10
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims description 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229940124784 gp41 inhibitor Drugs 0.000 claims description 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims description 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 7
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims 4
- 102100034343 Integrase Human genes 0.000 claims 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 90
- 0 *C(*)(C(O)=O)c1c(*)c(*)c2nc(*)[s]c2c1* Chemical compound *C(*)(C(O)=O)c1c(*)c(*)c2nc(*)[s]c2c1* 0.000 description 22
- 125000002619 bicyclic group Chemical group 0.000 description 17
- 125000004429 atom Chemical group 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 8
- 125000002877 alkyl aryl group Chemical group 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- ONTOQCPYIILKNF-QHCPKHFHSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)C)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)C)n1)c2-c(cc1)c2nccc3c2c1OCC3 ONTOQCPYIILKNF-QHCPKHFHSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 6
- 125000005024 alkenyl aryl group Chemical group 0.000 description 5
- 125000005217 alkenylheteroaryl group Chemical group 0.000 description 5
- 125000005025 alkynylaryl group Chemical group 0.000 description 5
- 125000000464 thioxo group Chemical group S=* 0.000 description 5
- -1 -OH Chemical group 0.000 description 4
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 4
- CNSHHSIPAVANBJ-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(N)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(N)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 CNSHHSIPAVANBJ-NRFANRHFSA-N 0.000 description 4
- VNIUQLUCZKZYPY-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3=CCCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3=CCCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 VNIUQLUCZKZYPY-SANMLTNESA-N 0.000 description 4
- IBRNRSAMSMSMNI-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(ccc1c2NCCO1)c2Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(ccc1c2NCCO1)c2Cl IBRNRSAMSMSMNI-NRFANRHFSA-N 0.000 description 4
- OPHMLEFZFXYRGK-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CCCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CCCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 OPHMLEFZFXYRGK-SANMLTNESA-N 0.000 description 4
- KABNRAXUBZHDIW-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CC3OCCO3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CC3OCCO3)n1)c2-c(cc1)c2nccc3c2c1OCC3 KABNRAXUBZHDIW-SANMLTNESA-N 0.000 description 4
- POCSGDIUHUYLDU-DEOSSOPVSA-N CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(C3CC3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(C3CC3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 POCSGDIUHUYLDU-DEOSSOPVSA-N 0.000 description 4
- BNYOCRBSHOESGQ-VWLOTQADSA-N CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(N3CCCC3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(N3CCCC3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 BNYOCRBSHOESGQ-VWLOTQADSA-N 0.000 description 4
- AQVUXWDSDLASCP-SANMLTNESA-N CC(C)CN(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)CN(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 AQVUXWDSDLASCP-SANMLTNESA-N 0.000 description 4
- XKCBCFFAQVLJPP-VWLOTQADSA-N CC(C)N(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)N(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 XKCBCFFAQVLJPP-VWLOTQADSA-N 0.000 description 4
- FKSKUTHBADGXQV-UHFFFAOYSA-N CCCc(cc1)c2nccc3c2c1OCC3 Chemical compound CCCc(cc1)c2nccc3c2c1OCC3 FKSKUTHBADGXQV-UHFFFAOYSA-N 0.000 description 4
- QEPFWYGLFVVATF-UHFFFAOYSA-N CCc(ccc1c2NCCO1)c2Cl Chemical compound CCc(ccc1c2NCCO1)c2Cl QEPFWYGLFVVATF-UHFFFAOYSA-N 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- BUZHUKSPYRHFDY-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(O)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(O)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 BUZHUKSPYRHFDY-NRFANRHFSA-N 0.000 description 3
- FFPMEFGSGLTLQQ-QHCPKHFHSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C3)CC3(F)F)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C3)CC3(F)F)n1)c2-c(cc1)c2nccc3c2c1OCC3 FFPMEFGSGLTLQQ-QHCPKHFHSA-N 0.000 description 3
- FFSUCMSAHKZCQM-DEOSSOPVSA-N CCN(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CCN(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 FFSUCMSAHKZCQM-DEOSSOPVSA-N 0.000 description 3
- KMVDCSWRPHYSNW-VWLOTQADSA-N CCN(CC)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CCN(CC)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 KMVDCSWRPHYSNW-VWLOTQADSA-N 0.000 description 3
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- KKTTTYWEPHZZGJ-VWLOTQADSA-N CC(C)(C)O[C@H](C(O)=O)C(C(C)(C)Cc1c2[s]c(N3CCCC3)n1)=C2c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)C(C(C)(C)Cc1c2[s]c(N3CCCC3)n1)=C2c(cc1)c2nccc3c2c1OCC3 KKTTTYWEPHZZGJ-VWLOTQADSA-N 0.000 description 2
- MMJAVOGVRGZCTK-KOKAMKNVSA-N CC(C)(C)O[C@H](C(O)=O)C(C(C)=CC1(C)N=C(N(C2)CC2F)SC11)=C1c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)C(C(C)=CC1(C)N=C(N(C2)CC2F)SC11)=C1c(cc1)c2nccc3c2c1OCC3 MMJAVOGVRGZCTK-KOKAMKNVSA-N 0.000 description 2
- BWBFIBKLVFCRRZ-DEOSSOPVSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)c(c1c2[s]c(N3CCC3)n1)F)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)c(c1c2[s]c(N3CCC3)n1)F)c2-c(cc1)c2nccc3c2c1OCC3 BWBFIBKLVFCRRZ-DEOSSOPVSA-N 0.000 description 2
- YHPBFFGJWJKHFP-VNYPPZAHSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)c1)c([C@@H]2C=CC(OCC3)=C4C3=CC=NC24)c2c1nc(N(C1)CC1OC)[s]2 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)c1)c([C@@H]2C=CC(OCC3)=C4C3=CC=NC24)c2c1nc(N(C1)CC1OC)[s]2 YHPBFFGJWJKHFP-VNYPPZAHSA-N 0.000 description 2
- RWNQJNPJKNIRPQ-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C#CC3CC3)n1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C#CC3CC3)n1)c2-c(cc1)ccc1Cl RWNQJNPJKNIRPQ-QFIPXVFZSA-N 0.000 description 2
- YYKPSBGSRCLNLC-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(C3=CCC3)=O)n1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(C3=CCC3)=O)n1)c2-c(cc1)ccc1Cl YYKPSBGSRCLNLC-NRFANRHFSA-N 0.000 description 2
- IHGNLBSUWZOMKH-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(F)F)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(F)F)n1)c2-c(cc1)c2nccc3c2c1OCC3 IHGNLBSUWZOMKH-NRFANRHFSA-N 0.000 description 2
- XNKZCAQOPVZICR-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(NC)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(NC)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 XNKZCAQOPVZICR-QFIPXVFZSA-N 0.000 description 2
- WLCQDHOBCPBVDE-LJAQVGFWSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(NCCc3ccccc3)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C(NCCc3ccccc3)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 WLCQDHOBCPBVDE-LJAQVGFWSA-N 0.000 description 2
- OKQVRVDVNUNJLE-SFHVURJKSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C)n1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C)n1)c2-c(cc1)ccc1Cl OKQVRVDVNUNJLE-SFHVURJKSA-N 0.000 description 2
- BKKQVBCBZUEZNO-VWLOTQADSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(cc1)c2c3c1OCCc3ccc2 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(cc1)c2c3c1OCCc3ccc2 BKKQVBCBZUEZNO-VWLOTQADSA-N 0.000 description 2
- LXQFTWXMBFKWOO-IBGZPJMESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CC3)n1)c2-c(cc1)ccc1Cl LXQFTWXMBFKWOO-IBGZPJMESA-N 0.000 description 2
- GATGEHOANDHODJ-VWLOTQADSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(C3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 GATGEHOANDHODJ-VWLOTQADSA-N 0.000 description 2
- KTHIXHOGFZDGQU-SFHVURJKSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)C)n1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)C)n1)c2-c(cc1)ccc1Cl KTHIXHOGFZDGQU-SFHVURJKSA-N 0.000 description 2
- HBLCFFKFUJOKPM-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CC(N(C)C)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CC(N(C)C)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 HBLCFFKFUJOKPM-SANMLTNESA-N 0.000 description 2
- QUHIZMHYCDHPBP-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CCN(C)C)n1)c2-c(cc1)c2nccc3c2c1OC=C3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CCN(C)C)n1)c2-c(cc1)c2nccc3c2c1OC=C3 QUHIZMHYCDHPBP-SANMLTNESA-N 0.000 description 2
- JKSQUQLVOKCXDY-SANMLTNESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CCN(C)C)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C)CCN(C)C)n1)c2-c(cc1)c2nccc3c2c1OCC3 JKSQUQLVOKCXDY-SANMLTNESA-N 0.000 description 2
- YAXATQNCQMPTJH-VWLOTQADSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C3)CC3OC)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N(C3)CC3OC)n1)c2-c(cc1)c2nccc3c2c1OCC3 YAXATQNCQMPTJH-VWLOTQADSA-N 0.000 description 2
- QKYAANCIOWEFCL-DEOSSOPVSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 QKYAANCIOWEFCL-DEOSSOPVSA-N 0.000 description 2
- DUPBLXCJZWLGJJ-QHCPKHFHSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(NC(C)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(NC(C)=O)n1)c2-c(cc1)c2nccc3c2c1OCC3 DUPBLXCJZWLGJJ-QHCPKHFHSA-N 0.000 description 2
- LHKQPSIXHISEBG-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(OC)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(OC)n1)c2-c(cc1)c2nccc3c2c1OCC3 LHKQPSIXHISEBG-QFIPXVFZSA-N 0.000 description 2
- VXQXKZFGLAWXHQ-KRWDZBQOSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]cn1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]cn1)c2-c(cc1)ccc1Cl VXQXKZFGLAWXHQ-KRWDZBQOSA-N 0.000 description 2
- IZJLCWALUKLIRA-LJAQVGFWSA-N CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(N(C)Cc3ccccc3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc(N(C)Cc3ccccc3)[s]c2c1-c(cc1)c2nccc3c2c1OCC3 IZJLCWALUKLIRA-LJAQVGFWSA-N 0.000 description 2
- GYPPWFPEPILFSY-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc[s]c2c1-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c1c(C)cc2nc[s]c2c1-c(cc1)c2nccc3c2c1OCC3 GYPPWFPEPILFSY-QFIPXVFZSA-N 0.000 description 2
- BNXMWEOPOXSTES-JLBRLKOWSA-N CC(C)CN(C)c1nc(cc(C)c([C@@H](C2OC2O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)CN(C)c1nc(cc(C)c([C@@H](C2OC2O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 BNXMWEOPOXSTES-JLBRLKOWSA-N 0.000 description 2
- CSXKRLUPICNVQN-SANMLTNESA-N CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 CSXKRLUPICNVQN-SANMLTNESA-N 0.000 description 2
- KJQUCTYWDHDJTQ-NRFANRHFSA-N CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)ccc3Cl)c2[s]1 Chemical compound CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)ccc3Cl)c2[s]1 KJQUCTYWDHDJTQ-NRFANRHFSA-N 0.000 description 2
- OECDHDLGRMTJSV-NRFANRHFSA-N CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c3ccccc3)c2[s]1 Chemical compound CC(C)Cc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c3ccccc3)c2[s]1 OECDHDLGRMTJSV-NRFANRHFSA-N 0.000 description 2
- ZVZXNNOMCBJDGE-DEOSSOPVSA-N CC(C)Oc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)Oc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 ZVZXNNOMCBJDGE-DEOSSOPVSA-N 0.000 description 2
- QCVBXIZQYVLBHU-DEOSSOPVSA-N CC(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C)c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 QCVBXIZQYVLBHU-DEOSSOPVSA-N 0.000 description 2
- OIABSFFLCBIDKW-VWLOTQADSA-N CC(C1)CN1c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 Chemical compound CC(C1)CN1c1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)c4nccc5c4c3OCC5)c2[s]1 OIABSFFLCBIDKW-VWLOTQADSA-N 0.000 description 2
- XUXGVCJDIYJVBF-VWLOTQADSA-N CCC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CCC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(N3CCC3)n1)c2-c(cc1)c2nccc3c2c1OCC3 XUXGVCJDIYJVBF-VWLOTQADSA-N 0.000 description 2
- BEVIWEXVWPBXKS-SANMLTNESA-N CCCc(c1c(cc2)O)ccnc1c2-c1c2[s]c(N(C)C(C)C)nc2cc(C)c1[C@@H](C(O)=O)OC(C)(C)C Chemical compound CCCc(c1c(cc2)O)ccnc1c2-c1c2[s]c(N(C)C(C)C)nc2cc(C)c1[C@@H](C(O)=O)OC(C)(C)C BEVIWEXVWPBXKS-SANMLTNESA-N 0.000 description 2
- OLVAECMLCCTDJN-IBGZPJMESA-N CCc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)ccc3Cl)c2[s]1 Chemical compound CCc1nc(cc(C)c([C@@H](C(O)=O)OC(C)(C)C)c2-c(cc3)ccc3Cl)c2[s]1 OLVAECMLCCTDJN-IBGZPJMESA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- MYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- NGAVGPXXRUWKNE-LJAQVGFWSA-N CC(C)(C)O[C@H](C(O)=O)C(C(C)(C)Cc1c2[s]c(C(NCc(cc3)ccc3OC)=O)n1)=C2c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)C(C(C)(C)Cc1c2[s]c(C(NCc(cc3)ccc3OC)=O)n1)=C2c(cc1)c2nccc3c2c1OCC3 NGAVGPXXRUWKNE-LJAQVGFWSA-N 0.000 description 1
- LTTPILDFUKYTLW-NDEPHWFRSA-N CC(C)(C)O[C@H](C(O)=O)c(c(-c(cc1)c2nccc3c2c1OCC3)c1S2)c(C)cc1N(Cc1c(C(F)(F)F)cccc1)C2=O Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(-c(cc1)c2nccc3c2c1OCC3)c1S2)c(C)cc1N(Cc1c(C(F)(F)F)cccc1)C2=O LTTPILDFUKYTLW-NDEPHWFRSA-N 0.000 description 1
- LUYLXLZUXUTSNR-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1C)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1C)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 LUYLXLZUXUTSNR-QFIPXVFZSA-N 0.000 description 1
- SDTLSRFUIFQDBY-NDEPHWFRSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1Cc2ccc(C(F)(F)F)cc2)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1Cc2ccc(C(F)(F)F)cc2)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 SDTLSRFUIFQDBY-NDEPHWFRSA-N 0.000 description 1
- CULOJJWOOHAGSV-NDEPHWFRSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1Cc2ccccc2)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc(N1Cc2ccccc2)c2SC1=O)c2-c(cc1)c2nccc3c2c1OCC3 CULOJJWOOHAGSV-NDEPHWFRSA-N 0.000 description 1
- PQMHDGGMINGNQR-PMERELPUSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(-c3cccc(-c(cccc4)c4F)c3)n1)c2-c(cc1)cc2c1OCCO2 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(-c3cccc(-c(cccc4)c4F)c3)n1)c2-c(cc1)cc2c1OCCO2 PQMHDGGMINGNQR-PMERELPUSA-N 0.000 description 1
- PTGHVHFZPNTZJV-YTTGMZPUSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(-c3ccnc(OCc4ccccc4)c3)n1)c2-c(cc1F)c(C)c2c1OCCC2 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)cc1c2[s]c(-c3ccnc(OCc4ccccc4)c3)n1)c2-c(cc1F)c(C)c2c1OCCC2 PTGHVHFZPNTZJV-YTTGMZPUSA-N 0.000 description 1
- TURCRXXRFZNVPN-UHFFFAOYSA-N CCC1C=CC=CC1C(F)(F)F Chemical compound CCC1C=CC=CC1C(F)(F)F TURCRXXRFZNVPN-UHFFFAOYSA-N 0.000 description 1
- VWDGMSAGDPRVEJ-UHFFFAOYSA-N CCCc(ccc1c2NCCO1)c2Cl Chemical compound CCCc(ccc1c2NCCO1)c2Cl VWDGMSAGDPRVEJ-UHFFFAOYSA-N 0.000 description 1
- IHHXYTIKYUHTQU-UHFFFAOYSA-N CCc1ccc(C(F)(F)F)cc1 Chemical compound CCc1ccc(C(F)(F)F)cc1 IHHXYTIKYUHTQU-UHFFFAOYSA-N 0.000 description 1
- CKQINTYJQOUAOQ-UHFFFAOYSA-N CCc1cccc(C(F)(F)F)c1 Chemical compound CCc1cccc(C(F)(F)F)c1 CKQINTYJQOUAOQ-UHFFFAOYSA-N 0.000 description 1
- YASSUAIJFUESOY-UHFFFAOYSA-N CN(C1)CC1(F)F Chemical compound CN(C1)CC1(F)F YASSUAIJFUESOY-UHFFFAOYSA-N 0.000 description 1
- ASGHRQMQKYGSJP-UHFFFAOYSA-N CN(C1)CC1S(C)(=O)=O Chemical compound CN(C1)CC1S(C)(=O)=O ASGHRQMQKYGSJP-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- AREYBIZUKSMRQI-UHFFFAOYSA-N Cc(cc1)c2nccc3c2c1OCC3 Chemical compound Cc(cc1)c2nccc3c2c1OCC3 AREYBIZUKSMRQI-UHFFFAOYSA-N 0.000 description 1
- AYTGARGOCPEHGL-UHFFFAOYSA-N Cc(cc1)cc2c1OCCO2 Chemical compound Cc(cc1)cc2c1OCCO2 AYTGARGOCPEHGL-UHFFFAOYSA-N 0.000 description 1
- GFZKZWGKJHWMTK-UHFFFAOYSA-N Cc(cc1F)c(C)c2c1OCCC2 Chemical compound Cc(cc1F)c(C)c2c1OCCC2 GFZKZWGKJHWMTK-UHFFFAOYSA-N 0.000 description 1
- BUIPKDFUVKLJTF-UHFFFAOYSA-N Cc1cc(-c(cccc2)c2F)ccc1 Chemical compound Cc1cc(-c(cccc2)c2F)ccc1 BUIPKDFUVKLJTF-UHFFFAOYSA-N 0.000 description 1
- BPCMDLPSVDEKRQ-UHFFFAOYSA-N Cc1cccc(-c(cncc2)c2OC)c1 Chemical compound Cc1cccc(-c(cncc2)c2OC)c1 BPCMDLPSVDEKRQ-UHFFFAOYSA-N 0.000 description 1
- DYIUSBBHMGWFIA-UHFFFAOYSA-N bromomethylbenzene;iodomethane Chemical compound IC.BrCC1=CC=CC=C1 DYIUSBBHMGWFIA-UHFFFAOYSA-N 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477922P | 2011-04-21 | 2011-04-21 | |
| US61/477,922 | 2011-04-21 | ||
| PCT/US2012/034593 WO2012145728A1 (en) | 2011-04-21 | 2012-04-20 | Benzothiazole compounds and their pharmaceutical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016012970A Division JP2016065110A (ja) | 2011-04-21 | 2016-01-27 | ベンゾチアゾール化合物およびその薬学的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514323A JP2014514323A (ja) | 2014-06-19 |
| JP2014514323A5 true JP2014514323A5 (enExample) | 2015-06-11 |
| JP5918848B2 JP5918848B2 (ja) | 2016-05-18 |
Family
ID=46028194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506609A Active JP5918848B2 (ja) | 2011-04-21 | 2012-04-20 | ベンゾチアゾール化合物およびその薬学的使用 |
| JP2016012970A Pending JP2016065110A (ja) | 2011-04-21 | 2016-01-27 | ベンゾチアゾール化合物およびその薬学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016012970A Pending JP2016065110A (ja) | 2011-04-21 | 2016-01-27 | ベンゾチアゾール化合物およびその薬学的使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9006229B2 (enExample) |
| EP (2) | EP3181555B1 (enExample) |
| JP (2) | JP5918848B2 (enExample) |
| KR (1) | KR20140027295A (enExample) |
| CN (2) | CN105712948A (enExample) |
| AP (2) | AP2013007249A0 (enExample) |
| AU (2) | AU2012245187B2 (enExample) |
| BR (1) | BR112013027096A2 (enExample) |
| CA (1) | CA2833377C (enExample) |
| CL (1) | CL2013003019A1 (enExample) |
| CO (1) | CO6801774A2 (enExample) |
| CR (1) | CR20130560A (enExample) |
| EA (1) | EA024952B1 (enExample) |
| EC (1) | ECSP13013021A (enExample) |
| ES (2) | ES2615734T3 (enExample) |
| IL (1) | IL228925A0 (enExample) |
| MA (1) | MA35804B1 (enExample) |
| MX (1) | MX2013012266A (enExample) |
| PE (1) | PE20141066A1 (enExample) |
| PH (2) | PH12013502180A1 (enExample) |
| PT (1) | PT2699558T (enExample) |
| SG (1) | SG194512A1 (enExample) |
| UA (1) | UA111841C2 (enExample) |
| WO (1) | WO2012145728A1 (enExample) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| EP3070081B1 (en) | 2012-04-20 | 2018-02-28 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| JP5941598B2 (ja) | 2013-01-09 | 2016-06-29 | ギリアード サイエンシーズ， インコーポレイテッド | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 |
| NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
| TW201441197A (zh) * | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| PL3019503T3 (pl) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| US9944656B2 (en) | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| EA201790024A1 (ru) | 2014-07-11 | 2017-07-31 | Джилид Сайэнс, Инк. | Модуляторы toll-подобных рецепторов для лечения вич |
| CN107001357A (zh) * | 2014-08-27 | 2017-08-01 | Viiv保健英国第五有限公司 | 用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物 |
| WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| ES2705709T3 (es) | 2014-12-24 | 2019-03-26 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento del VIH |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3277691B1 (en) | 2015-04-02 | 2019-01-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| WO2017048727A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
| JP2018529714A (ja) | 2015-09-30 | 2018-10-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための化合物および組合せ物 |
| EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
| JP6716785B2 (ja) | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| ES2992772T3 (en) | 2016-09-28 | 2024-12-18 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
| EP3532478B1 (en) | 2016-10-27 | 2021-05-26 | Gilead Sciences, Inc. | Crystalline form of darunavir free base |
| EP3565809A1 (en) | 2017-01-03 | 2019-11-13 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| JP7287906B2 (ja) | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| US11229638B2 (en) | 2017-08-22 | 2022-01-25 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| KR102497051B1 (ko) | 2018-01-19 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | 빅테그라비르의 대사물 |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| PE20210685A1 (es) | 2018-07-03 | 2021-04-08 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y metodos de uso |
| KR102629921B1 (ko) | 2018-07-06 | 2024-01-31 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI766172B (zh) | 2018-07-30 | 2022-06-01 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| CA3113011A1 (en) | 2018-09-19 | 2020-03-26 | Gilead Sciences, Inc. | Integrase inhibitors for the prevention of hiv |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| IL295677A (en) | 2020-02-24 | 2022-10-01 | Gilead Sciences Inc | Tetracyclic compounds for treating hiv infection |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| US12421235B2 (en) | 2020-09-30 | 2025-09-23 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PT4244396T (pt) | 2020-11-11 | 2025-10-20 | Gilead Sciences Inc | Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120 |
| PT4196479T (pt) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | Compostos de piridotriazinas substituídos e suas utilizações |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202434566A (zh) | 2022-07-01 | 2024-09-01 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| CA3265134A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences Inc | DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AU2024259111A1 (en) | 2023-04-19 | 2025-10-16 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| US20250051375A1 (en) | 2023-05-31 | 2025-02-13 | Gilead Sciences, Inc. | Anti-hiv compounds |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025076542A1 (en) | 2023-10-05 | 2025-04-10 | Jones R Brad | Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025212814A1 (en) | 2024-04-03 | 2025-10-09 | Gilead Sciences, Inc. | Anti-hiv compounds |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895028A (en) * | 1972-09-12 | 1975-07-15 | Tokyo Tanabe Co | Alpha-(2-phenylbenzothiazol-5-yl)propionic acid |
| JPS4994667A (enExample) * | 1973-01-23 | 1974-09-09 | ||
| FR2453163A1 (fr) * | 1979-04-03 | 1980-10-31 | Rolland Sa A | Derives de benzothiazole, leur procede de preparation et leurs applications en therapeutique |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| GB8403739D0 (en) * | 1984-02-13 | 1984-03-14 | Roussel Lab Ltd | Chemical compounds |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US5733906A (en) | 1993-10-12 | 1998-03-31 | Eli Lilly And Company | Inhibitors of HIV Protease useful for the treatment of Aids |
| MX9308016A (es) | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
| CA2159639A1 (en) | 1993-04-02 | 1994-10-13 | Vincent J. Miles | Method for selective inactivation of viral replication |
| JP3287558B2 (ja) | 1993-07-27 | 2002-06-04 | 株式会社半導体エネルギー研究所 | 半導体装置の作製方法 |
| US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
| DE4428932A1 (de) | 1994-08-16 | 1996-02-22 | Hoechst Ag | Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AU747500B2 (en) | 1998-04-09 | 2002-05-16 | Merck & Co., Inc. | Oxidation process using periodic acid |
| WO2000063152A1 (en) | 1999-02-22 | 2000-10-26 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Acetylated and related analogues of chicoric acid as hiv integrase inhibitors |
| US20020052323A1 (en) | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
| JP3836791B2 (ja) | 2000-11-21 | 2006-10-25 | サネシス ファーマシューティカルズ， インコーポレイテッド | リガンドの迅速な同定のための拡張されたテザー化アプローチ |
| FR2819507B1 (fr) | 2001-01-17 | 2007-09-28 | Inst Rech Developpement Ird | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
| FR2839646B1 (fr) | 2002-05-17 | 2008-04-11 | Bioalliance Pharma | Utilisation de derives de quinoleine a effet anti-integrase et ses applications |
| BR0305717A (pt) * | 2002-08-02 | 2004-09-28 | Tibotec Pharm Ltd | Inibidores da protease do hiv 2-amino-benzotiazol sulfonamida de amplo espectro |
| CN101445493A (zh) * | 2002-08-02 | 2009-06-03 | 泰博特克药品有限公司 | 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂 |
| AU2003257822A1 (en) | 2002-08-13 | 2004-04-30 | Shionogi And Co., Ltd. | Heterocyclic compound having hiv integrase inhibitory activity |
| EP2371955A1 (en) | 2002-09-26 | 2011-10-05 | K.U. Leuven Research & Development | Integrase cofactor |
| AR042095A1 (es) | 2002-11-20 | 2005-06-08 | Japan Tobacco Inc | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| CA2567851A1 (en) | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| US7087610B2 (en) * | 2004-06-03 | 2006-08-08 | Bristol-Myers Squibb Company | Benzothiazole antiviral agents |
| EP1773750A1 (en) | 2004-06-22 | 2007-04-18 | Smithkline Beecham Corporation | Chemical compounds |
| TWI306401B (en) | 2004-08-13 | 2009-02-21 | Nat Health Research Institutes | Benzothiazolium compounds |
| US20060094755A1 (en) | 2004-10-28 | 2006-05-04 | Bioflexis, Llc | Novel quinoline-based metal chelators as antiviral agents |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| CA2651979A1 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| JO2841B1 (en) * | 2006-06-23 | 2014-09-15 | تيبوتيك فارماسيوتيكالز ليمتد | 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV) |
| US8435774B2 (en) | 2006-06-28 | 2013-05-07 | Qiagen Gmbh | Enhancing reactivation of thermostable reversibly inactivated enzymes |
| WO2008053478A2 (en) | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| CA2671478C (en) | 2006-12-13 | 2015-02-17 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| US8377960B2 (en) | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| RU2503679C2 (ru) | 2007-11-15 | 2014-01-10 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| CA2705338A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| GB0801940D0 (en) | 2008-02-01 | 2008-03-12 | Univ Leuven Kath | Inhibitors of lentiviral replication |
| JP2011511005A (ja) | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | ２−アミノピリジン系キナーゼ阻害薬 |
| EP2362775B1 (en) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemical compounds |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX336687B (es) | 2009-06-30 | 2016-01-28 | Siga Technologies Inc | Tratamiento y prevencion de infecciones del virus del dengue. |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| ES2475970T3 (es) | 2009-12-23 | 2014-07-11 | Katholieke Universiteit Leuven | Novedosos compuestos antivirales |
| US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| NZ603644A (en) | 2010-05-24 | 2014-10-31 | Univ Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| KR20140003438A (ko) | 2010-11-15 | 2014-01-09 | 카톨리에케 유니버시테이트 루벤 | 항바이러스성 축합 헤테로사이클릭 화합물 |
| BR112013011991A2 (pt) | 2010-11-15 | 2016-08-30 | Viiv Healthcare Uk Ltd | composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit. |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| AU2012209373A1 (en) | 2011-01-24 | 2013-04-11 | Glaxosmithkline Llc | Isoquinoline compounds and methods for treating HIV |
| TW201302760A (zh) | 2011-04-04 | 2013-01-16 | Gilead Sciences Inc | 製備ｈｉｖ整合酶抑制劑之方法 |
| AU2012240313A1 (en) | 2011-04-04 | 2013-05-02 | Gilead Sciences, Inc. | Solid state forms of HIV inhibitor |
| EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2511273B8 (en) | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| SG194216A1 (en) | 2011-04-21 | 2013-11-29 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| CN103608350B (zh) | 2011-04-21 | 2015-11-25 | 拜耳知识产权有限责任公司 | 三唑并吡啶类化合物 |
| JP6222776B2 (ja) | 2011-04-21 | 2017-11-01 | オリゲニス ゲーエムベーハーＯｒｉｇｅｎｉｓ Ｇｍｂｈ | キナ−ゼ・インヒビタ−として有用なピラゾロ［４，３−ｄ］ピリミジン |
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| WO2013002357A1 (ja) | 2011-06-30 | 2013-01-03 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| ES2632443T3 (es) | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| WO2013058448A1 (ko) | 2011-10-20 | 2013-04-25 | 한국해양연구원 | 내분비계 장애물질 노출에 대응하는 바다송사리 유전자 및 이를 이용한 수생태계 환경오염 진단 방법 |
| JP6099149B2 (ja) | 2011-10-25 | 2017-03-22 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| US8332160B1 (en) * | 2011-11-17 | 2012-12-11 | Amyris Biotechnologies, Inc. | Systems and methods for engineering nucleic acid constructs using scoring techniques |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013157622A1 (ja) | 2012-04-19 | 2013-10-24 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| EP3070081B1 (en) | 2012-04-20 | 2018-02-28 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| AU2013288369B2 (en) | 2012-07-12 | 2018-03-29 | Viiv Healthcare Uk Limited | Compounds and methods for treating HIV |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20140094609A1 (en) | 2012-10-03 | 2014-04-03 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
| WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
-
2012
- 2012-04-20 WO PCT/US2012/034593 patent/WO2012145728A1/en not_active Ceased
- 2012-04-20 JP JP2014506609A patent/JP5918848B2/ja active Active
- 2012-04-20 ES ES12719182.3T patent/ES2615734T3/es active Active
- 2012-04-20 CN CN201610177497.3A patent/CN105712948A/zh active Pending
- 2012-04-20 SG SG2013077110A patent/SG194512A1/en unknown
- 2012-04-20 EP EP16196723.7A patent/EP3181555B1/en active Active
- 2012-04-20 AP AP2013007249A patent/AP2013007249A0/xx unknown
- 2012-04-20 AU AU2012245187A patent/AU2012245187B2/en active Active
- 2012-04-20 MX MX2013012266A patent/MX2013012266A/es unknown
- 2012-04-20 BR BR112013027096A patent/BR112013027096A2/pt not_active IP Right Cessation
- 2012-04-20 KR KR1020137030857A patent/KR20140027295A/ko not_active Withdrawn
- 2012-04-20 EA EA201391395A patent/EA024952B1/ru unknown
- 2012-04-20 AP AP2015008931A patent/AP2015008931A0/xx unknown
- 2012-04-20 UA UAA201312204A patent/UA111841C2/uk unknown
- 2012-04-20 EP EP12719182.3A patent/EP2699558B1/en active Active
- 2012-04-20 PE PE2013002347A patent/PE20141066A1/es not_active Application Discontinuation
- 2012-04-20 PH PH1/2013/502180A patent/PH12013502180A1/en unknown
- 2012-04-20 ES ES16196723T patent/ES2707997T3/es active Active
- 2012-04-20 US US14/112,473 patent/US9006229B2/en active Active
- 2012-04-20 PT PT127191823T patent/PT2699558T/pt unknown
- 2012-04-20 CA CA2833377A patent/CA2833377C/en active Active
- 2012-04-20 CN CN201280029211.7A patent/CN103797001B/zh active Active
-
2013
- 2013-10-17 CL CL2013003019A patent/CL2013003019A1/es unknown
- 2013-10-17 IL IL228925A patent/IL228925A0/en unknown
- 2013-10-31 CR CR20130560A patent/CR20130560A/es unknown
- 2013-11-14 MA MA36432A patent/MA35804B1/fr unknown
- 2013-11-14 CO CO13268123A patent/CO6801774A2/es unknown
- 2013-11-14 EC ECSP13013021 patent/ECSP13013021A/es unknown
-
2015
- 2015-02-26 US US14/632,771 patent/US9464096B2/en active Active
- 2015-09-11 PH PH12015502056A patent/PH12015502056A1/en unknown
-
2016
- 2016-01-27 JP JP2016012970A patent/JP2016065110A/ja active Pending
- 2016-09-06 US US15/257,482 patent/US9879023B2/en active Active
- 2016-09-29 AU AU2016234985A patent/AU2016234985C1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514323A5 (enExample) | ||
| JP2013533885A5 (enExample) | ||
| JP2013535426A5 (enExample) | ||
| JP5918848B2 (ja) | ベンゾチアゾール化合物およびその薬学的使用 | |
| JP2019509276A5 (enExample) | ||
| DK2558095T3 (en) | ORGANIC RELATIONSHIP FOR USE IN TREATMENT OF DELIVERY CANCER | |
| JP2017528487A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| JP2020503374A5 (enExample) | ||
| RU2012137501A (ru) | Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли | |
| JP2016527217A5 (enExample) | ||
| JP2016510043A5 (enExample) | ||
| JP2010510999A5 (enExample) | ||
| AR082079A1 (es) | Derivados del acido 2-naftalen-acetico, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de la proliferacion del virus hiv | |
| JP2010529147A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2010516700A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| JP2017526724A5 (enExample) | ||
| RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм | |
| JP2007522159A5 (enExample) |